Clinical Research Directory

Inclusion Criteria: * Healthy male and female adults aged 18 to 55 years inclusive at Screening. * Body mass index between 18 and 32 kg/m² inclusive and weight of at least 50 kg at Screening. * Healthy in the opinion of the Principal Investigator, based on medical history, physical examination, 12-lead ECG, vital signs, and clinical laboratory assessments. * Female participants must be non-lactating and either of non-childbearing potential, postmenopausal, or, if of childbearing potential, must have negative pregnancy tests and agree to required contraception and ova donation restrictions. * Male participants must agree to sperm donation restrictions and required contraception measures. * For Part A only, participants must not be of Asian descent due to increased risk associated with carbamazepine exposure. * Able to provide signed informed consent and comply with study requirements, including dietary restrictions and confinement at the clinical research unit. Exclusion Criteria: * History of contraindication or hypersensitivity to radiprodil, carbamazepine, itraconazole, or formulation components. * For Part A only, HLA genotypes associated with increased risk of carbamazepine-induced severe cutaneous adverse reactions. * Any medical condition that, in the opinion of the Principal Investigator, would pose additional risk or interfere with drug absorption, distribution, metabolism, or excretion. * Pregnancy, breastfeeding, or positive pregnancy test. * Significant neuropsychiatric, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, urologic, neurological, malignancy, psychiatric disease, brain surgery, or brain injury. * Clinically significant allergic conditions. * History of illicit drug abuse or alcohol abuse within 2 years of Screening. * History of suicide attempt, deliberate self-harm, significant suicidal ideation, or suicidal behaviour on C-SSRS. * Excessive alcohol or caffeine consumption. * Positive drug, alcohol, cotinine, or relevant substance screen at Screening or Day -1. * Recent marijuana, tobacco, nicotine, prescription drug, investigational product, OTC medication, herbal product, vaccine, blood donation, acute illness, relevant surgery, or blood transfusion as defined in the protocol. * Positive serology for HBsAg, HCV antibody, or HIV antibody. * Abnormal blood pressure, pulse rate, clinically significant ECG abnormality, QTcF \>450 msec, or history of prolonged QT syndrome. * Restricted food or drink consumption before dosing, including alcohol, grapefruit/pomelo/star fruit/Seville orange products, poppy seeds, and xanthine-containing products. * Poor venous access. * Women of childbearing potential using oral, injected, or implanted hormonal contraception.